1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Arovella Therapeutics Limited

Arovella Therapeutics Limited

AASX:ALA
0.05
AUD
+0.00
(-3.92%)
-0.01EPS
74.95MMarket Cap
Feb 25Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
0.19
0.1
0.09
0.11
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.05
-0.06
-0.04
-0.02
-0.08
-0.07
-0.06
-0.02
-0.02
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.27
0.28
0.27
0.25
0.17
0.08
0.02
0.02
0.01
- -
0.01
0.02
0.01
Tangible Book Value per Share
0.03
0.07
0.04
0.03
-0.06
0.02
- -
0.01
0.01
- -
0.01
0.02
0.01
Basic Weighted Avg Shares
45
55
62
63
66
116
168
331
550
711
941
1,097
1,201
Sales/Revenue/Turnover
9
6
6
7
- -
1
1
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-22.4
-72.55
-45.02
-20.03
-1,433.85
-193.24
-900.23
-1,813.16
-2,568.01
-2,385.02
-63,595.65
-8,237.35
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
- -
Net Income, GAAP
-2
-3
-2
-1
-5
-8
-10
-5
-9
-10
-9
-8
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-23.73
-59.86
-38.56
-17.21
-1,281.93
-639.42
-1,866.73
-1,961.35
-2,914.23
-2,508.35
-51,447.26
-5,521.45
- -
Working Capital
10
12
4
3
-3
4
- -
6
5
3
11
20
14
LT Debt
4
- -
- -
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
16
19
17
17
11
14
4
9
8
4
11
20
14
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-19.88
-21.57
-13.15
-7.39
-38.56
-61.28
-109.8
-76.96
-103.87
-178.67
-116.55
-47.98
-40.41

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.86%
36.15%
-29.51%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
37.03%
10.55%
-7.89%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.01
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nicole Louise van der Weerden
Full Time Employees
27
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Corporate One Preston VIC Australia 3072
IPO Date
Nov 7, 2001
Website
arovella.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Arovella Therapeutics Limited (ASX: ALA) is a biotechnology company that develops invariant natural killer T (iNKT) cell therapies for blood cancers and solid tumors. The company offers ALA-101, an off-the-shelf CAR19-iNKT cell therapy targeting CD19-positive B-cell lymphomas and leukemias including non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia and hairy cell leukemia; ALA-105, a CLDN18.2-targeting CAR-iNKT cell therapy licensed exclusively from Sparx Group for gastric, gastroesophageal junction and pancreatic cancers; and an expanding pipeline incorporating IL-12-TM cytokine armoring technology, plus chimeric antigen receptors under option from Baylor College of Medicine targeting GD2 for neuroblastoma and GPC3 for hepatocellular carcinoma. Founded in 1999 and headquartered in Preston, Australia, Arovella operates primarily in Australia with international clinical development plans focused on the US FDA. Recent developments include appointing SAPRO as contract research organization for the ALA-101 Phase 1 trial in October 2025, holding a successful Type D meeting with the FDA, exercising an exclusive option with Baylor College of Medicine in November 2025 for additional CAR and iNKT intellectual property, appointing former CSL Chief Scientific Officer Dr. Andrew Nash to the board, establishing an internal lab at Jumar Bioincubator, completing cGMP manufacturing process transfer for ALA-101, raising A$15 million via placement to fund Phase 1 enrollment and initial data readout, and advancing IND submission targeted for acceptance in late 2025 ahead of first-in-human dosing in early 2026.

Company News

Company News APIChatGPT

  • gurufocus.com

    Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches